In this session from the WFH 2020 Virtual Summit, Steve Kitchen, Emmanuel Favaloro, Robert Gosselin and Geoffrey Kershaw discuss: How the emergence of chromogenic factor VIII testing has illuminated both discrepancies between testing methods and potential issues associated with product potency assessment How the creation of B-domain deleted recombinant factor VIII replacement product has initiated […]
On December 10th, 2020 Glenn Pierce, WFH VP Medical moderated this one-hour webinar in the Public Health Webinar Series on Blood Disorders presented by the CDC. The webinar discussed how the WFH Guidelines for the Management of Hemophilia, 3rd edition provides opportunities to improve the standard of diagnosis and care for people with hemophilia around […]
Adapted from: Global NMO Training 2016 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael This second module in the Treatment Products eLearning Program explains the evolution of products for the treatment of bleeding disorders, from products derived from blood to artificially produced clotting factor concentrates (CFCs) with extended half-lives (EHL). […]
In the Wednesday morning session on new technologies, Dan Hart presents an overview of technologies promising to impact the care of people with hemophilia.
In the Thursday morning session on bleeding and response to treatment, David Page discusses how to define a bleed.
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.